Price Alert

Ultragenyx Pharmaceutical... (RARE)

NASDAQ: RARE · Real-Time Price · USD

29.83

0.82 (2.83%)

At close: Aug 15, 2025, 1:05 PM

Ultragenyx Pharmaceutical Statistics

Share Statistics

Ultragenyx Pharmaceutical has 94.54M shares outstanding. The number of shares has increased by 2.58% in one year.

Shares Outstanding	94.54M
Shares Change (YoY)	2.58%
Shares Change (QoQ)	2.21%
Owned by Institutions (%)	90.48%
Shares Floating	90.09M
Failed to Deliver (FTD) Shares	1,237
FTD / Avg. Volume	0.06%

Short Selling Information

The latest short interest is 8.8M, so 9.31% of the outstanding shares have been sold short.

Short Interest	8.8M
Short % of Shares Out	9.31%
Short % of Float	9.65%
Short Ratio (days to cover)	2.49

Valuation Ratios

The PE ratio is -6.69 and the forward PE ratio is -7.22. Ultragenyx Pharmaceutical's PEG ratio is 0.28.

PE Ratio	-6.69
Forward PE	-7.22
PS Ratio	6.8
Forward PS	3.3
PB Ratio	14.92
P/FCF Ratio	-9.03
PEG Ratio	0.28

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Ultragenyx Pharmaceutical.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.37, with a Debt / Equity ratio of 3.56.

Current Ratio	2.37
Quick Ratio	2.24
Debt / Equity	3.56
Debt / EBITDA	-1.94
Debt / FCF	-2.16
Interest Coverage	-8.5

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$432.94K
Profits Per Employee	$-439.86K
Employee Count	1,294
Asset Turnover	0.37
Inventory Turnover	1.7

Taxes

Income Tax	1.6M
Effective Tax Rate	-0.28%

Stock Price Statistics

The stock price has increased by -46.19% in the last 52 weeks. The beta is 0.24, so Ultragenyx Pharmaceutical's price volatility has been higher than the market average.

Beta	0.24
52-Week Price Change	-46.19%
50-Day Moving Average	33.19
200-Day Moving Average	39.92
Relative Strength Index (RSI)	37.6
Average Volume (20 Days)	2,065,514

Income Statement

In the last 12 months, Ultragenyx Pharmaceutical had revenue of 560.23M and earned -569.18M in profits. Earnings per share was -6.29.

Revenue	560.23M
Gross Profit	483.5M
Operating Income	-535.97M
Net Income	-569.18M
EBITDA	-469M
EBIT	-504.55M
Earnings Per Share (EPS)	-6.29

Full Income Statement

Balance Sheet

The company has 173.73M in cash and 910.01M in debt, giving a net cash position of -736.28M.

Cash & Cash Equivalents	173.73M
Total Debt	910.01M
Net Cash	-736.28M
Retained Earnings	-3.96B
Total Assets	1.31B
Working Capital	426.54M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -414.19M and capital expenditures -7.49M, giving a free cash flow of -421.68M.

Operating Cash Flow	-414.19M
Capital Expenditures	-7.49M
Free Cash Flow	-421.68M
FCF Per Share	-4.66

Full Cash Flow Statement

Margins

Gross margin is 86.3%, with operating and profit margins of -95.67% and -101.6%.

Gross Margin	86.3%
Operating Margin	-95.67%
Pretax Margin	-101.31%
Profit Margin	-101.6%
EBITDA Margin	-83.72%
EBIT Margin	-95.67%
FCF Margin	-75.27%

Dividends & Yields

RARE does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for RARE is $75, which is 173.8% higher than the current price. The consensus rating is "Buy".

Price Target	$75
Price Target Difference	173.8%
Analyst Consensus	Buy
Analyst Count	12

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-3.47
Piotroski F-Score	4